Evidence-Based Management of Adult Insomnia
Cognitive Behavioral Therapy for Insomnia (CBT-I) is the mandatory first-line treatment for all adults with chronic insomnia and must be initiated before or alongside any medication. 1, 2
First-Line Treatment: CBT-I
CBT-I provides superior long-term efficacy compared to all pharmacologic agents, with sustained benefits persisting up to 2 years after treatment ends, whereas medication effects cease when stopped. 1, 2, 3, 4
Core Components (All Evidence-Based)
Stimulus control therapy – Use the bed only for sleep; leave the bed if unable to fall asleep within ~20 minutes and return only when drowsy. 1, 2, 5, 6
Sleep restriction therapy – Limit time in bed to actual sleep time + 30 minutes (minimum 5 hours); adjust weekly based on sleep efficiency (total sleep time ÷ time in bed × 100%). This is especially effective for sleep-maintenance problems. 1, 2, 5, 6
Cognitive restructuring – Systematically challenge maladaptive beliefs such as "I cannot sleep without medication" or "My life will be ruined if I can't sleep." 1, 2, 6
Relaxation techniques – Progressive muscle relaxation, guided imagery, or controlled breathing to lower physiological arousal. Notably, relaxation may be counterproductive in some patients and is not essential. 1, 2, 6
Sleep hygiene education – Maintain consistent sleep-wake schedule, avoid caffeine ≥6 hours before bed, eliminate screens ≥1 hour before sleep, keep bedroom dark/cool/quiet. Sleep hygiene alone is insufficient as monotherapy and must be combined with other CBT-I components. 1, 2, 5
Delivery Formats (All Effective)
CBT-I can be delivered via individual therapy, group sessions, telephone-based programs, web-based modules, or self-help books—all formats demonstrate comparable efficacy. In-person therapist-led programs show the highest remission rates. 1, 2, 6
Pharmacologic Options (Only After CBT-I Initiation)
Pharmacotherapy should supplement—not replace—CBT-I, and should be prescribed at the lowest effective dose for the shortest duration (typically ≤4 weeks for acute insomnia). 1, 2, 7, 8
For Sleep-Onset Insomnia
Zolpidem 10 mg (5 mg if age ≥65 years) – Reduces sleep-onset latency by ~25 minutes; take within 30 minutes of bedtime with ≥7 hours remaining before awakening. 1, 2
Zaleplon 10 mg (5 mg if age ≥65 years) – Ultrashort half-life (~1 hour); minimal next-day sedation; can be used for middle-of-night awakenings when ≥4 hours remain. 1, 2
Ramelteon 8 mg – Melatonin-receptor agonist with no abuse potential, no DEA scheduling, no withdrawal; preferred for patients with substance-use history. 1, 2
For Sleep-Maintenance Insomnia
Low-dose doxepin 3–6 mg – Reduces wake after sleep onset by 22–23 minutes; minimal anticholinergic effects at hypnotic doses; no abuse potential. This is the preferred first-line hypnotic for sleep-maintenance problems. 1, 2, 9
Suvorexant 10 mg – Orexin-receptor antagonist; reduces wake after sleep onset by 16–28 minutes; lower risk of cognitive/psychomotor impairment than benzodiazepine-type agents. 1, 2
For Combined Sleep-Onset and Maintenance Insomnia
Eszopiclone 2–3 mg (1 mg if age ≥65 years or hepatic impairment) – Increases total sleep time by 28–57 minutes; moderate-to-large improvement in subjective sleep quality. 1, 2
Daridorexant – Orexin-receptor antagonist approved for up to 3 months or longer in selected cases. 2, 7, 10
Duration and Monitoring
Reassess after 1–2 weeks to evaluate sleep-onset latency, total sleep time, nocturnal awakenings, daytime functioning, and adverse effects. 1, 2
FDA labeling limits hypnotics to ≤4 weeks for acute insomnia; evidence beyond this period is insufficient. 1, 2, 7, 8
Orexin-receptor antagonists (suvorexant, daridorexant, lemborexant) may be continued for up to 3 months or longer in selected patients. 2, 7, 11
Medications Explicitly NOT Recommended
Strong Recommendations Against
Trazodone – Yields only ~10 minutes reduction in sleep latency with no improvement in subjective sleep quality; adverse events in ~75% of older adults; harms outweigh benefits. 1, 2
Over-the-counter antihistamines (diphenhydramine, doxylamine) – Lack efficacy data; strong anticholinergic effects (confusion, urinary retention, falls, daytime sedation, delirium); tolerance develops within 3–4 days. 1, 2, 7, 8
Antipsychotics (quetiapine, olanzapine) – Weak evidence for insomnia benefit; significant risks including weight gain, metabolic syndrome, extrapyramidal symptoms, increased mortality in elderly with dementia. 1, 2, 7, 8
Traditional benzodiazepines (lorazepam, clonazepam, diazepam) – Long half-lives cause drug accumulation, daytime sedation, higher fall/cognitive-impairment risk; associations with dementia and fractures. 1, 2
Melatonin supplements – Produce only ~9 minutes reduction in sleep latency; insufficient evidence for chronic insomnia. 1, 2, 7, 8
Herbal supplements (valerian, L-tryptophan, lemon balm) – Insufficient evidence to support use for primary insomnia. 1, 2, 5, 7, 8
Treatment Algorithm
Step 1 (Week 0)
Initiate CBT-I immediately for all patients with chronic insomnia, incorporating stimulus control, sleep restriction, cognitive restructuring, and sleep hygiene education. 1, 2, 6
Step 2 (Week 0–4)
If CBT-I alone is insufficient after 4–8 weeks, add first-line pharmacotherapy matched to the insomnia phenotype:
- Sleep-onset difficulty → zaleplon, ramelteon, or zolpidem (age-adjusted dosing)
- Sleep-maintenance difficulty → low-dose doxepin or suvorexant
- Combined difficulty → eszopiclone or daridorexant 1, 2
Step 3 (Week 1–2)
Reassess sleep parameters and adverse effects; adjust dose or switch to an alternative agent within the same class if response is inadequate. 1, 2
Step 4 (Week 4+)
Document continued need for medication; if effective, plan gradual taper while maintaining CBT-I. If ineffective after multiple first-line agents, evaluate for underlying sleep disorders (sleep apnea, restless-legs syndrome, circadian-rhythm disorders). 1, 2, 5
Special Population Considerations
Older Adults (≥65 Years)
Reduce all hypnotic doses: zolpidem ≤5 mg, eszopiclone ≤2 mg, zaleplon ≤5 mg, doxepin ≤6 mg. 1, 2
Low-dose doxepin 3 mg and ramelteon 8 mg are the safest first-line options due to minimal fall risk and cognitive impairment. 1, 2
Avoid all anticholinergic agents (antihistamines, high-dose tricyclics) due to confusion, urinary retention, falls, and delirium risk. 1, 2
Patients with Comorbid Depression/Anxiety
- Sedating antidepressants (mirtazapine 7.5–30 mg, low-dose doxepin) may be considered as third-line options after benzodiazepine-receptor agonists have failed, especially when comorbid mood disorders are present. 1, 2
Critical Safety Warnings
All benzodiazepine-receptor agonists carry FDA warnings for complex sleep behaviors (sleep-driving, sleep-walking, sleep-eating); discontinue immediately if these occur. 1, 2
Combining multiple sedating agents markedly increases risk of respiratory depression, cognitive impairment, falls, and fractures. 1, 2
Observational data link hypnotic use to increased dementia, fractures, and major injuries, though causality is unproven. 1, 2
Persistent insomnia beyond 7–10 days despite treatment requires evaluation for underlying sleep disorders such as sleep apnea, restless-legs syndrome, or circadian-rhythm disorders. 1, 2
Common Pitfalls to Avoid
Initiating pharmacotherapy without first implementing CBT-I – This violates strong guideline recommendations and yields less durable benefit. 1, 2, 6
Using adult dosing in older adults – Age-adjusted dosing is mandatory to reduce fall risk. 1, 2
Prescribing trazodone, OTC antihistamines, or antipsychotics for primary insomnia – These lack efficacy and carry significant safety concerns. 1, 2, 7, 8
Continuing hypnotics beyond 4 weeks without periodic reassessment – FDA labeling limits use to short-term; document rationale for longer durations. 1, 2
Failing to match medication to insomnia phenotype – Use zaleplon for onset only, doxepin for maintenance only, eszopiclone for combined symptoms. 1, 2